Full Press Release Details
odronextamab recommended for eu approval by the chmp to treat relapsed refractory follicular lymphoma and diffuse large b cell lymphoma.
REGN
odronextamab recommended for eu approval by the chmp to treat relapsed refractory follicular lymphoma and diffuse large b cell lymphoma
Key Takeaway: odronextamab recommended for eu approval by the chmp to treat relapsed refractory follicular lymphoma and diffuse large b cell lymphoma